Price$7.16-0.85 (-10.67%)
2026-05-212026-08-25
News · 26 weeks38-33%
2026-03-012026-08-23
Mix1990d
- Other9(47%)
- SEC Filings5(26%)
- Earnings2(11%)
- Leadership1(5%)
- Offering1(5%)
- Insider1(5%)
Latest news
25 items- SECDarioHealth Corp. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - DarioHealth Corp. (0001533998) (Filer)
- ANALYSTAlliance Global Partners initiated coverage on DarioHealth with a new price targetAlliance Global Partners initiated coverage of DarioHealth with a rating of Buy and set a new price target of $12.00
- PRDarioHealth Reports Second Quarter 2026 Financial ResultsSecond quarter 2026 revenue was $5.2 million, reflecting the Company's strategic decision to discontinue certain pharmaceutical-related businessGross margin increased to 62%, compared to 57% in the first quarter of 2026 and 55% in the second quarter of 2025; non-GAAP B2B2C gross margin was approximately 80% for the 10th consecutive quarterOperating loss decreased by 30% year-over-year and 11% quarter-over-quarterOperating expenses declined by 21% year-over-year and 8% quarter-over-quarterMulti-condition strategy compounding: more than 80% of the $13.1 million in contracted and late-stage annual recurring revenue ("ARR") is multi-conditionCommercial momentum with three significant wins in rec
- SECSEC Form 10-Q filed by DarioHealth Corp.10-Q - DarioHealth Corp. (0001533998) (Filer)
- PRDario Expands Provider-Backed Cardiometabolic Platform with New Women's Health and Sleep Solutions Aligning with Client DemandNew programs, expected to begin revenue contribution Q4 2026, extend Dario's integrated healthcare platform into two high-impact clinical categories while advancing execution of the Company's provider-backed care strategyAI-enabled programs combine digital engagement, human behavioral coaching and clinical care to improve outcomes while expanding Dario's participation in reimbursement-driven healthcare servicesNEW YORK, Aug. 4, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced it has further expanded its provider-backed cardiometa
- PRDarioHealth to Report Second Quarter 2026 Results on Tuesday, August 11, 2026Company to host conference call and webcast at 8:30 a.m. Eastern TimeNEW YORK, Aug. 3, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leading artificial intelligence ("AI")-powered healthcare technology company transforming the management of chronic conditions, announced today that it will release its financial results for the 2nd quarter ended June 30th, 2026 and will host a conference call and webcast at 8:30 a.m. Eastern Time, on Tuesday, August 11th, 2026, before the market opens. Erez Raphael, Chief Executive Officer, Lara Dodo, Chief Operations Officer, and Chen Franco-Yehuda, Chief Financial Officer, will host the call.Conference Call DetailsDate: T
- PRDario Launches Integrated GLP-1 Program, Combining Its Digital Chronic Care Platform with Provider-Backed Clinical Care in a Single End-to-End ExperienceFirst commercial offering from Dario's collaboration with Beluga Health adds licensed provider evaluation, prescribing and ongoing clinical oversight directly inside Dario's chronic care platform Commercial availability expected Fall 2026, with revenue contribution anticipated late 2026 and ramping through 2027 Launch addresses a market in which employers and health plans are reducing GLP-1 coverage and members are increasingly accessing care through consumer channels Available through three channels: Dario's direct-to-consumer shop, health plan marketplaces and employer B2B2C programs NEW YORK, July 30, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" o
- INSIDERDirector Matheis Dennis converted options into 965 shares and bought $100,000 worth of shares (14,430 units at $6.93), increasing direct ownership by 56% to 43,026 units (SEC Form 4)4 - DarioHealth Corp. (0001533998) (Issuer)
- SECDarioHealth Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - DarioHealth Corp. (0001533998) (Filer)
- SECSEC Form 424B5 filed by DarioHealth Corp.424B5 - DarioHealth Corp. (0001533998) (Filer)
- PRDario Announces Pricing of a $23.5 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq RulesThe financing was led by continued support of existing long-term institutional investors along with participation from a new global fundamental institutional investorNEW YORK, July 22, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company," "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced that it has entered into securities purchase agreements with current long term Dario institutional investors as well as new fundamental investors for the purchase and sale of 3,454,559 shares of common stock (or common stock equivalents in lieu thereof), at a price of $6.80 per share, in a registered
- PRFortune 50 Employer Awards Dario Contract to Deliver AI-Powered Cardiometabolic Care PlatformContract award for over 100,000 eligible employees marks Dario's fifth Fortune 50 client, further reflecting growing demand among large employers for integrated, outcomes-driven chronic condition managementProgram expected to launch Fall 2026, with revenue contribution beginning by year-end and ramping through 2027NEW YORK, July 16, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced another Fortune 50 employer has selected Dario to provide its integrated digital cardiometabolic care platform for employees living with diabetes and/o
- PRDario Expects Proprietary AI Engine DarioIQ™ to Increase Recurring Revenue from Existing Customers by 10-15%DarioIQ drives higher engagement and retention, better clinical outcomes, higher client ROI and recurring revenue growth for DarioDario IQ's AI-driven personalization increases member engagement by 40% and improves member retention by 20% by leveraging 13+ billion proprietary real-world healthcare data pointsNEW YORK, July 13, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company," "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced the Company expects broader deployment of DarioIQ™, its proprietary, responsible generative and agentic AI platform, to increase annual Business-to-Business-
- SECDarioHealth Corp. filed SEC Form 8-K: Leadership Update8-K - DarioHealth Corp. (0001533998) (Filer)
- PRDario Signs New Agreement with a Major Health Insurer in Arizona Representing Hundreds of Thousands of Lives Through Amwell PartnershipAgreement representative of Dario's channel-led growth strategy to bring cardiometabolic digital health solution at scale to self-insured employers seeking measurable reductions in cardiometabolic risk and total cost of care via payer relationships NEW YORK, July 6, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced a new agreement with a major health insurer with a stronghold in Arizona, entered into through its strategic channel partnership with Amwell. This opportunity makes Dario's cardiometabolic solution available to the insurer's Administrative Services Only ("ASO") book of business, repre
- PRTop National Health Plan Extends Agreement for Mental Health and Expands Dario Partnership into Cardiometabolic Care, Demonstrating Successful Multi-Condition Growth StrategyThird health plan customer to expand beyond initial deployment, reinforcing Dario's land-and-expand strategy and creating significant opportunity to grow revenue within existing customer baseNEW YORK, July 2, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in AI-powered digital health solutions, today announced that one of the 5 largest health insurers in the U.S. has extended its initial agreement and expanded its relationship with Dario by adding the Company's hypertension solution, following success with Dario's behavioral health offering. The health plan's roll out of Dario's cardiometabolic care significantly increases the address
- PRDario Appoints Former Humana Chief Compliance Officer Sean O'Reilly to Advisory Board to Support Strategic Growth and Healthcare PartnershipsO'Reilly's extensive experience across healthcare compliance, risk management, regulatory oversight and payer operations expected to support Dario's continued expansion with health plans, employers and providers as Dario moves closer to careO'Reilly's track record of leveraging advanced data analytics and AI in supporting value-based care strongly aligned with Dario's AI transitionNEW YORK, June 30, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in AI-enabled digital health solutions, today announced the appointment of Sean O'Reilly to its Advisory Board. The appointment reflects Dario's continued focus on strengthening its strategic
- PRDario Announces Strategic Collaboration with Beluga Health to Deliver Provider-Backed, Integrated Care at ScaleDario's best-in-class, consumer-centric chronic care platform, combined now with Beluga's embedded clinical delivery, extends member engagement to include provider-delivered treatment, lowering costs and expanding value for existing clients while opening large new marketsNEW YORK, June 29, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in AI-powered digital health solutions, today announced it has entered into a Collaborative Services Agreement ("Agreement") with Beluga Health, P.A. ("Beluga"), establishing a strategic partnership to deliver a provider-backed, digitally-enabled model for longitudinal care, population health and qualit
- PRDario Presents Four Studies at American Diabetes Association Scientific Sessions Highlighting Commercial and Clinical Value of its Digital Health PlatformData from a total of 27 studies presented at ADA over 8 years reinforce Dario's strategic move closer to care, expanding revenue model into claims-based and outcomes-driven payments serving health plans, employers and other enterprise buyers Weight loss of 6.4% with Dario alone, and 14.3% when combined with a GLP-1 at 12 months, exceeding benchmarks based on medications alone44.8% of high-risk diabetes users achieved at least a 1% eA1c reduction at 12 monthsNEW YORK, June 8, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced presentation of four studies at the American Diabetes Association's ("ADA
- PRDario More Than Doubles Addressable Market in Solera Health's Network via Expanded Hypertension Program, With Dario Now Reaching Greater Than 500,000 Eligible LivesExpansion driven by highly successful partnership based on Dario's consistent ability to engage members and deliver scalable value across cardiometabolic conditions NEW YORK, May 26, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced that its largest network partner to date, Solera Health, a leading digital health network connecting curated solutions to employers, health plans and other payers, has broadened Dario's digital health offerings on its platform to include an expanded hypertension program. Hypertension represents one of the largest unmet needs in healthcare, affecting nearly half of all
- PRDarioHealth Reports First Quarter 2026 Financial and Operating ResultsFirst quarter 2026 revenues increased to $5.6 million, marking the second consecutive quarter of sequential growthOperating expenses decreased by 21% year-over-year and decreased by 8% quarter-over-quarterOperating loss decreased by 22% year-over-year and decreased by 15% quarter-over-quarter; Non-GAAP operating loss decreased by 8% year-over-year and decreased by 11% quarter-over-quarterChannel partnerships through Solera, Amwell and other blue-chip partners provide access to over 116 million covered livesNow in contracting phase with new channel partner that, upon finalization, would extend Dario's reach to a combined 175+ million covered lives and add one of the largest hospital networks
- SECSEC Form 10-Q filed by DarioHealth Corp.10-Q - DarioHealth Corp. (0001533998) (Filer)
- SECSEC Form SD filed by DarioHealth Corp.SD - DarioHealth Corp. (0001533998) (Filer)
- PRDarioHealth to Report First Quarter 2026 Results on Wednesday, May 13, 2026Company to host conference call and webcast at 8:30 a.m. Eastern TimeNEW YORK, May 4, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release its financial results for the 1st quarter ended March 31st, 2026 and will host a conference call and webcast at 8:30 a.m. Eastern Time, on Wednesday, May 13th, 2026, before the market opens. Erez Raphael, Chief Executive Officer, Steven Nelson, President and Chief Commercial Officer, and Chen Franco-Yehuda, Chief Financial Officer, will host the call.Conference Call DetailsDate: Wednesday, May13th, 2026, 8:30 a.m. Eastern TimeDial-in Number: 1-80
- PRDario Demonstrates Improved Workplace Function and Productivity Outcomes Through Digital Behavioral Health Program: Real-World Study Published in JMIR Formative ResearchFindings highlight the role of continuous behavioral support in improving focus, productivity and day-to-day functioning – key priorities for employers and health plansStatistically significant improvements in workplace functioning highlight the potential economic value of Dario's digital health solutions for payersNEW YORK, April 20, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced the publication of new peer-reviewed research in JMIR Formative Research demonstrating meaningful improvements in workplace functioning among participants using Dario's digital behavioral health program. The study, t
DRIO FAQ
6 questionsWhat does DarioHealth Corp. do?
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario Tools, which are devices that integrate with applications on a user's smartphone; DarioEngage, a population health management platform; and the Dario Loop, an AI-driven journey engine. It also sells device-specific disposables test strip cartridges, lancets, and Dario Blood Glucose Monitoring System; and Dario Smart Diabetes Management Solution, which includes tools to help diabetic patients manage their disease. The company was...Where does DRIO stock trade?
DarioHealth Corp. (DRIO) is listed on NASDAQ.What sector and industry is DRIO in?
DarioHealth Corp. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about DRIO?
DarioHealth Corp. has had 5 recent analyst actions on file. The most recent action was from Alliance Global Partners: Buy with a $1200.00 price target on 2026-08-19.What companies are similar to DRIO?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare DRIO side-by-side with any of them on Quantisnow.How can I track DRIO on Quantisnow?
Quantisnow aggregates DarioHealth Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DRIO to receive live email and push alerts on every new disclosure.